Literature DB >> 20216404

Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma.

Rita A Sakr1, Violetta Barbashina, Mary Morrogh, Sarat Chandarlapaty, Victor P Andrade, Crispinita D Arroyo, Narciso Olvera, Tari A King.   

Abstract

The PI3K/PTEN pathway plays a major role in carcinogenesis. Dysregulation of this pathway occurs frequently in breast cancer, and loss of PTEN expression is emerging as a potentially important mechanism of resistance to the widely used anti-HER2 therapy, trastuzumab. However, assays for loss of PTEN expression have suffered from lack of consistency. Here, we describe an automated and reliable protocol for PTEN protein expression by immunohistochemistry in formalin-fixed paraffin-embedded tissue that can be easily incorporated into clinical trials.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20216404      PMCID： PMC2921801          DOI： 10.1097/PAI.0b013e3181d50bd5

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN： 1533-4058


  12 in total

1.  Loss of PTEN expression as a prognostic marker for tongue cancer.

Authors:  J I Lee; J C Soria; K A Hassan; A K El-Naggar; X Tang; D D Liu; W K Hong; L Mao
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2001-12

2.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers.

Authors:  P A Steck; M A Pershouse; S A Jasser; W K Yung; H Lin; A H Ligon; L A Langford; M L Baumgard; T Hattier; T Davis; C Frye; R Hu; B Swedlund; D H Teng; S V Tavtigian
Journal:  Nat Genet       Date:  1997-04       Impact factor: 38.330

3.  Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.

Authors:  E Rhei; L Kang; F Bogomolniy; M G Federici; P I Borgen; J Boyd
Journal:  Cancer Res       Date:  1997-09-01       Impact factor: 12.701

4.  Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer.

Authors:  George V Thomas; Steve Horvath; Bradley L Smith; Katherine Crosby; Lori A Lebel; Matthew Schrage; Jonathan Said; Jean De Kernion; Robert E Reiter; Charles L Sawyers
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

5.  Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast.

Authors:  A Perren; L P Weng; A H Boag; U Ziebold; K Thakore; P L Dahia; P Komminoth; J A Lees; L M Mulligan; G L Mutter; C Eng
Journal:  Am J Pathol       Date:  1999-10       Impact factor: 4.307

6.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Authors:  Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

Review 7.  Human cancer, PTEN and the PI-3 kinase pathway.

Authors:  Ramon Parsons
Journal:  Semin Cell Dev Biol       Date:  2004-04       Impact factor: 7.727

8.  Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab.

Authors:  Dana Faratian; Alexey Goltsov; Galina Lebedeva; Anatoly Sorokin; Stuart Moodie; Peter Mullen; Charlene Kay; In Hwa Um; Simon Langdon; Igor Goryanin; David J Harrison
Journal:  Cancer Res       Date:  2009-07-28       Impact factor: 12.701

9.  Promoter methylation of the PTEN gene is a common molecular change in breast cancer.

Authors:  Jose M García; Javier Silva; Cristina Peña; Vanesa Garcia; Rufo Rodríguez; Miguel A Cruz; Blanca Cantos; Mariano Provencio; Pilar España; Felix Bonilla
Journal:  Genes Chromosomes Cancer       Date:  2004-10       Impact factor: 5.006

10.  Reduced expression of PTEN correlates with breast cancer progression.

Authors:  Shikha Bose; Allison Crane; Hanina Hibshoosh; Mahesh Mansukhani; Lynn Sandweis; Ramon Parsons
Journal:  Hum Pathol       Date:  2002-04       Impact factor: 3.466
View more
  31 in total

1.  Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial.

Authors:  Edith A Perez; Amylou C Dueck; Ann E McCullough; Beiyun Chen; Xochiquetzal J Geiger; Robert B Jenkins; Wilma L Lingle; Nancy E Davidson; Silvana Martino; Peter A Kaufman; Leila A Kutteh; George W Sledge; Lyndsay N Harris; Julie R Gralow; Monica M Reinholz
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

2.  PI3K pathway activation in high-grade ductal carcinoma in situ--implications for progression to invasive breast carcinoma.

Authors:  Rita A Sakr; Britta Weigelt; Sarat Chandarlapaty; Victor P Andrade; Elena Guerini-Rocco; Dilip Giri; Charlotte K Y Ng; Catherine F Cowell; Neal Rosen; Jorge S Reis-Filho; Tari A King
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

Review 3.  HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.

Authors:  Devika Gajria; Sarat Chandarlapaty
Journal:  Expert Rev Anticancer Ther       Date:  2011-02       Impact factor: 4.512

4.  A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.

Authors:  Lillian M Smyth; Kelsey R Monson; Komal Jhaveri; Alexander Drilon; Bob T Li; Wassim Abida; Gopa Iyer; John F Gerecitano; Mrinal Gounder; James J Harding; Martin H Voss; Vicky Makker; Alan L Ho; Pedram Razavi; Alexia Iasonos; Philip Bialer; Mario E Lacouture; Jerrold B Teitcher; Joseph P Erinjeri; Nora Katabi; Matthew G Fury; David M Hyman
Journal:  Invest New Drugs       Date:  2017-03-09       Impact factor: 3.850

5.  Biomarkers That Predict Sensitivity to Heat Shock Protein 90 Inhibitors.

Authors:  Komal Jhaveri; Sarat Chandarlapaty; Neil Iyengar; Patrick G Morris; Adriana D Corben; Sujata Patil; Muzaffar Akram; Russell Towers; Rita A Sakr; Tari A King; Larry Norton; Neal Rosen; Clifford Hudis; Shanu Modi
Journal:  Clin Breast Cancer       Date:  2015-11-19       Impact factor: 3.225

6.  Genomic complexity and AKT dependence in serous ovarian cancer.

Authors:  Aphrothiti J Hanrahan; Nikolaus Schultz; Maggie L Westfal; Rita A Sakr; Dilip D Giri; Stefano Scarperi; Manickam Janakiraman; Manickam Janikariman; Narciso Olvera; Ellen V Stevens; Qing-Bai She; Carol Aghajanian; Tari A King; Elisa de Stanchina; David R Spriggs; Adriana Heguy; Barry S Taylor; Chris Sander; Neal Rosen; Douglas A Levine; David B Solit
Journal:  Cancer Discov       Date:  2012-01       Impact factor: 39.397

7.  Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors.

Authors:  David M Hyman; Alexandra E Snyder; Richard D Carvajal; John F Gerecitano; Martin H Voss; Alan L Ho; Jason Konner; Jennifer L Winkelmann; Megan A Stasi; Kelsey R Monson; Alexia Iasonos; David R Spriggs; Philip Bialer; Mario E Lacouture; Jerrold B Teitcher; Nora Katabi; Matthew G Fury
Journal:  Cancer Chemother Pharmacol       Date:  2015-02-12       Impact factor: 3.333

8.  Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.

Authors:  Sarat Chandarlapaty; Rita A Sakr; Dilip Giri; Sujata Patil; Adriana Heguy; Monica Morrow; Shanu Modi; Larry Norton; Neal Rosen; Clifford Hudis; Tari A King
Journal:  Clin Cancer Res       Date:  2012-10-23       Impact factor: 12.531

9.  Regional differences in gallbladder cancer pathogenesis: insights from a comparison of cell cycle-regulatory, PI3K, and pro-angiogenic protein expression.

Authors:  Jean M Butte; Javiera Torres; Emanuela F Veras; Kenichi Matsuo; Mithat Gönen; Michael I D'Angelica; Enrique Waugh; Manuel Meneses; Yoshiyaki Inayama; Yuman Fong; Ronald P Dematteo; Hernan De La Fuente; Itaru Endo; David S Klimstra; William R Jarnagin
Journal:  Ann Surg Oncol       Date:  2012-12-01       Impact factor: 5.344

10.  Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations.

Authors:  Jennifer J Wheler; Apostolia M Tsimberidou; Gerald S Falchook; Ralph G Zinner; David S Hong; Jansina Y Fok; Siqing Fu; Sarina A Piha-Paul; Aung Naing; Razelle Kurzrock
Journal:  Mol Cancer Ther       Date:  2013-08-20       Impact factor: 6.261
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.